Menu
- Office Hour : 08:00am - 6:00pm
At Cohance Lifesciences, we bring together the power of precision chemistry, bioconjugation expertise, and GMP manufacturing to accelerate Antibody-Drug Conjugate (ADC) development from discovery to clinic. Our integrated approach spans innovative payload and linker development, bioconjugation strategies, and clinical-grade manufacturing — all under one agile, compliant platform.
With NJ Bio as our strategic partner, we offer a CRDMO model purpose-built for ADCs — combining deep scientific insight with end-to-end execution. Whether it’s optimizing cytotoxic payloads or scaling conjugated molecules for clinical supply, Cohance Lifesciences is your trusted partner for success in the evolving ADC landscape.
• CPT & Auristatin derivative synthesis
• Proprietary s-Trione-based payloads
• Industry-standard & custom linkers
• Containment expertise for high-potency synthesis
• Linker-payload optimization and bioconjugation
• Phase-appropriate GMP manufacturing
• Analytical development & regulatory documentation
• Discovery to IND support, tech transfer, and scale-up